CervoMed Inc. (CRVO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $25.57M
Last updated: Nov 17, 2026 at 11:04 AM ET
CervoMed Inc. (CRVO) Stock Forecast
Analysts expect CervoMed (CRVO) to earn -$2.28 per share in the fiscal year ending Dec 31, 2026. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 6 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$2.28
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.19
- EPS consensus
- Next report
- Mar 11, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.28 | -$2.30 to -$2.25 | 2 |
| Dec 31, 2027 | -$1.19 | -$1.62 to -$0.68 | 4 |
Quarterly Estimates
The EPS consensus rises from -$0.53 for the quarter ending Dec 31, 2026 to -$0.27 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.53 | -$0.74 to -$0.43 | 8 |
| Mar 31, 2027 | -$0.27 | -$0.45 to -$0.13 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 1 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.11.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.28 | -$2.13 | -$2.20 | -$2.20 | -$2.11 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.19 | -$1.39 | -$1.48 | -$1.48 | -$1.53 | N/A |
| Quarter ending Mar 31, 2027 | -$0.27 | -$0.40 | -$0.42 | -$0.42 | -$0.35 | N/A |
Frequently Asked Questions About CRVO
What is the CRVO stock forecast?
Consensus analyst estimates put CervoMed's EPS at -$2.28 for the fiscal year ending Dec 31, 2026. The consensus rating from 6 analysts is Buy.
How do analysts rate CRVO stock?
Of 6 analysts covering CervoMed, 0 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CRVO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.28, with estimates from -$2.30 to -$2.25 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.19, with estimates from -$1.62 to -$0.68 from 4 analysts.
How many analysts cover CRVO?
6 analysts rate CervoMed stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CRVO pages: Overview, Earnings, Forecast, Financials, Competitors